Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

New York 3/1/2021 12:23:00 PM

Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.  

The University of Texas at Austin has identified a new drug “DHA-dFdC” that has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.

DHA-dFdc is a new compound that holds promising indications of becoming the next generation of chemotherapy treatment for advanced pancreatic cancer
- Inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that gemcitabine, a current standard therapy)
- Has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model
- Overcomes tumor cell resistance to current chemotherapeutic drugs
- Is well tolerated in preclinical toxicity test
- Has demonstrated activities against other cancers (e.g. leukemia, lung, melanoma)
- May stimulate immunogenic cell death to activate host anti-tumor immunity

More News

https://s3.amazonaws.com/findit-pictures/351133/5a9367a7-1d67-477a-8321-e8a4173d690f.jpg

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Released On: 3/5/2021
Views: 446

https://s3.amazonaws.com/findit-pictures/351133/b9cc6d12-45b2-42d8-98c3-1ea2961eecad.jpg

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Released On: 3/3/2021
Views: 430

https://s3.amazonaws.com/findit-pictures/351133/86c80767-4bb8-48ba-b5be-f5c6e1ff2d4d.jpg

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Released On: 3/1/2021
Views: 443

https://s3.amazonaws.com/findit-pictures/351133/d1155add-3bd8-4751-8661-f9c48c2f069d.jpg

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

Released On: 3/1/2021
Views: 789

https://s3.amazonaws.com/findit-pictures/351133/48a25696-dac4-4e6d-bc52-6d181debb131.jpg

Meet Aikido Pharma Inc’s Board of Directors

Meet Aikido Pharma Inc’s Board of Directors

Released On: 2/28/2021
Views: 463

https://s3.amazonaws.com/findit-pictures/351133/06f2c09a-2436-4e6b-8eb3-f07578c8ab17.jpg

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

Released On: 2/23/2021
Views: 514

https://s3.amazonaws.com/findit-pictures/351133/bf0df713-8e2e-44ac-9609-f12bdf9847eb.jpg

Artificial Intelligence Is Optimizing Drug Development

Artificial Intelligence Is Optimizing Drug Development

Released On: 2/22/2021
Views: 522

https://s3.amazonaws.com/findit-pictures/351133/fad82173-54eb-4dcf-b365-5cf437598e16.jpg

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Released On: 2/20/2021
Views: 415

https://s3.amazonaws.com/findit-pictures/351133/f5052f01-a9c3-48cf-8558-12b7f8dd5d85.jpg

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Released On: 2/19/2021
Views: 571

https://s3.amazonaws.com/findit-pictures/351133/9642dc86-4305-4113-a789-78af0ea01972.jpg

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

Released On: 2/16/2021
Views: 657

https://s3.amazonaws.com/findit-pictures/351133/d64287af-b96d-47bb-a32b-65ddb76ff3d4.jpg

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Released On: 2/16/2021
Views: 596

https://s3.amazonaws.com/findit-pictures/351133/54fa1d0c-edd2-4000-b922-08b0837dba1a.jpg

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

Released On: 2/16/2021
Views: 654

https://s3.amazonaws.com/findit-pictures/351133/d6d4252d-f996-436f-bf91-6c83af43e756.jpg

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Released On: 2/15/2021
Views: 423

https://s3.amazonaws.com/findit-pictures/351133/8ac95bfe-f94b-4b9f-b39a-98d7aa7f6abd.jpg

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Released On: 2/10/2021
Views: 342

https://s3.amazonaws.com/findit-pictures/351133/cdbebd8e-c86d-4537-8940-1b1b2ea0b06e.jpg

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Released On: 2/9/2021
Views: 814

https://s3.amazonaws.com/findit-pictures/351133/09f4b098-397e-40d6-8af9-bacf930bb0cf.jpg

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Released On: 2/5/2021
Views: 455

https://s3.amazonaws.com/findit-pictures/351133/59ca97a6-b0e3-47f3-adef-57939fddd0e5.jpg

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Released On: 2/3/2021
Views: 1061

https://s3.amazonaws.com/findit-pictures/351133/e6e1220e-0686-4d01-8029-a87b9d54e412.jpg

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Released On: 2/3/2021
Views: 536

Load More wait

Map

Aikido Pharma

Get Directions

Aikido Pharma

  • One Rockefeller Plaza
    New York, New York 10020
    United States
  • (212) 745-1373